EP2406229A1 - 2-mercaptoquinoléine-3-carboxamides substitués utilisés comme modulateurs des canaux kcnq2/3 - Google Patents

2-mercaptoquinoléine-3-carboxamides substitués utilisés comme modulateurs des canaux kcnq2/3

Info

Publication number
EP2406229A1
EP2406229A1 EP10708726A EP10708726A EP2406229A1 EP 2406229 A1 EP2406229 A1 EP 2406229A1 EP 10708726 A EP10708726 A EP 10708726A EP 10708726 A EP10708726 A EP 10708726A EP 2406229 A1 EP2406229 A1 EP 2406229A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
methyl
quinoline
carboxamide
ethylsulfanyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10708726A
Other languages
German (de)
English (en)
Inventor
Sven KÜHNERT
Gregor Bahrenberg
Achim Kless
Wolfgang Schröder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40671387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2406229(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Priority to EP10708726A priority Critical patent/EP2406229A1/fr
Publication of EP2406229A1 publication Critical patent/EP2406229A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Abstract

L'invention concerne des 2-mercaptoquinoléine-3-carboxamides substitués, leurs procédés de production, des médicaments contenant ces composés et l'utilisation de ces composés pour la production de médicaments.
EP10708726A 2009-03-12 2010-03-11 2-mercaptoquinoléine-3-carboxamides substitués utilisés comme modulateurs des canaux kcnq2/3 Withdrawn EP2406229A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10708726A EP2406229A1 (fr) 2009-03-12 2010-03-11 2-mercaptoquinoléine-3-carboxamides substitués utilisés comme modulateurs des canaux kcnq2/3

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09003597 2009-03-12
PCT/EP2010/001509 WO2010102811A1 (fr) 2009-03-12 2010-03-11 2-mercaptoquinoléine-3-carboxamides substitués utilisés comme modulateurs des canaux kcnq2/3
EP10708726A EP2406229A1 (fr) 2009-03-12 2010-03-11 2-mercaptoquinoléine-3-carboxamides substitués utilisés comme modulateurs des canaux kcnq2/3

Publications (1)

Publication Number Publication Date
EP2406229A1 true EP2406229A1 (fr) 2012-01-18

Family

ID=40671387

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10708726A Withdrawn EP2406229A1 (fr) 2009-03-12 2010-03-11 2-mercaptoquinoléine-3-carboxamides substitués utilisés comme modulateurs des canaux kcnq2/3

Country Status (20)

Country Link
US (2) US20100234372A1 (fr)
EP (1) EP2406229A1 (fr)
JP (1) JP5727946B2 (fr)
KR (1) KR20110132590A (fr)
CN (1) CN102348692A (fr)
AR (1) AR075824A1 (fr)
AU (1) AU2010223513B2 (fr)
BR (1) BRPI1008939A2 (fr)
CA (1) CA2755004A1 (fr)
CL (1) CL2011002209A1 (fr)
CO (1) CO6410292A2 (fr)
EC (1) ECSP11011348A (fr)
IL (1) IL214945A0 (fr)
MX (1) MX2011009369A (fr)
NZ (1) NZ595625A (fr)
PE (1) PE20120790A1 (fr)
RU (1) RU2011141188A (fr)
TW (1) TWI461197B (fr)
WO (1) WO2010102811A1 (fr)
ZA (1) ZA201107444B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010102778A2 (fr) * 2009-03-10 2010-09-16 Grünenthal GmbH 3-aminoisoxazolopyridines substituées en tant que modulateurs de kcnq 2/3
TWI504395B (zh) * 2009-03-10 2015-10-21 Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
TW201038565A (en) 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
TWI475020B (zh) 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
ES2537628T3 (es) 2010-08-27 2015-06-10 Grünenthal GmbH 2-Oxiquinolin-3-carboxamidas sustituidas como moduladores de KCNQ2/3
CN103189357B (zh) 2010-08-27 2015-11-25 格吕伦塔尔有限公司 作为kcnq2/3调节剂的取代的2-氧代-和2-硫代-二氢喹啉-3-甲酰胺
US8618129B2 (en) 2010-09-01 2013-12-31 Gruenenthal Gmbh Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as KCNQ2/3 modulators
WO2014056620A1 (fr) 2012-10-11 2014-04-17 Grünenthal GmbH Prévention et/ou traitement des maladies et/ou troubles induits par tspo
WO2014082737A1 (fr) * 2012-11-28 2014-06-05 Grunenthal Gmbh Carboxamides spécifiques utilisés en tant que modulateurs des canaux kcnq2/3
US9248122B2 (en) 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
EP2925759A1 (fr) 2012-11-28 2015-10-07 Grünenthal GmbH Hétéroquinoline-3-carboxamides utilisés en tant que modulateurs kcnq2/3
AU2014212426B8 (en) * 2013-01-31 2018-05-10 Vertex Pharmaceuticals Incorporated Quinoline and Quinoxaline Amides as Modulators of Sodium Channels
JP2016511237A (ja) 2013-02-01 2016-04-14 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 選択的ｈｄａｃ３阻害剤
US9139583B2 (en) 2013-02-01 2015-09-22 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
AU2014219024B2 (en) 2013-02-20 2018-04-05 KALA BIO, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
AU2014342042B2 (en) 2013-11-01 2017-08-17 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
PH12015000236A1 (en) * 2015-07-06 2017-01-23 Samsung Electronics Co Ltd Electronic device for providing a calibrated keyboard configuration
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
BR112019004463A2 (pt) 2016-09-08 2019-05-28 Kala Pharmaceuticals Inc formas cristalinas de compostos terapêuticos, seus processos de obtenção e seus métodos de uso
CA3036336A1 (fr) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Formes cristallines de composes therapeutiques et leurs utilisations
JP7120549B2 (ja) * 2016-12-15 2022-08-17 小野薬品工業株式会社 Ｔｒｅｋ（ｔｗｉｋ関連ｋチャネル）チャネルのアクチベータ
DE102018212006B3 (de) 2018-07-18 2019-10-31 Universität Greifswald Thioether als Modulatoren von Kv7.2/Kv7.3-Kanälen

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2706977A1 (de) 1977-02-18 1978-08-24 Hoechst Ag Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
FR2532939A1 (fr) * 1982-09-13 1984-03-16 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus
DE4032147A1 (de) 1990-10-10 1992-04-16 Bayer Ag Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung
EP0716077A1 (fr) 1994-12-08 1996-06-12 Ciba-Geigy Ag Amides d'acides oméga-amino alcanoiques et diamides alcanoiques ayant un substituant aromatique et leur application en tant qu'inhibiteurs de leur rénine
WO1996026925A1 (fr) 1995-03-01 1996-09-06 Banyu Pharmaceutical Co., Ltd. Derives de l'arylthioacetamide
DE19738616A1 (de) 1997-09-04 1999-03-11 Clariant Gmbh 4-Hydroxychinolin-3-carbonsäure-Derivate als Lichtschutzmittel
DE19738615A1 (de) * 1997-09-04 1999-03-11 Clariant Gmbh Neue Lichtschutzmittel auf Basis von sterisch gehinderten Aminen
EP1147094A1 (fr) * 1999-01-15 2001-10-24 Novo Nordisk A/S Agonistes non peptidiques de glp-1
WO2001010381A2 (fr) 1999-08-04 2001-02-15 Icagen, Inc. Procedes therapeutiques ou prophylactiques de la douleur et de l'anxiete
JP2003506387A (ja) 1999-08-04 2003-02-18 アイカゲン インコーポレイテッド カリウムチャンネルオープナーとしてのベンズアニリド
WO2002072088A2 (fr) * 2001-02-20 2002-09-19 Bristol-Myers Squibb Company Modulateurs de canaux potassiques kcnq et leur utilisation dans le traitement de la migraine et de maladies liees a la migraine d'un point de vue mecanistique
CZ20032233A3 (cs) 2001-02-20 2004-12-15 Bristol-Myers Squibb Company Derivát 2,4-disubstituovaného pyrimidin-5-karboxamidu jako modulátor draslíkového kanálku KCNQ
US6593349B2 (en) 2001-03-19 2003-07-15 Icagen, Inc. Bisarylamines as potassium channel openers
US7087758B2 (en) * 2001-04-06 2006-08-08 Smithkline Beecham Corporation Quinoline inhibitors of hyaki and hyak3 kinases
EP1542966A1 (fr) 2002-09-17 2005-06-22 Pharmacia Corporation Modulateurs des recepteurs hepatiques x aromatiques
DE60335028D1 (de) 2002-12-23 2010-12-30 Icagen Inc Quinazolinone als kaliumkanalmodulatoren
EP1449841A1 (fr) 2003-02-19 2004-08-25 Bayer CropScience SA Nouveaux composés fungicides
US7598412B2 (en) 2003-10-08 2009-10-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
EA200601830A1 (ru) 2004-05-04 2007-04-27 Пфайзер Инк. Ортозамещённые арильные или гетероарильные амидные соединения
ME02970B (fr) * 2004-06-24 2018-07-20 Vertex Pharma Modulateurs de transporteurs de cassette de liaison a l ́ATP
CA2585490A1 (fr) 2004-11-12 2006-05-18 Galapagos Nv Composes heteroaromatiques de l'azote qui se lient au site actif d'enzymes de type proteines kinases
EP2298766B1 (fr) 2005-03-03 2013-09-18 H. Lundbeck A/S Formulations pharmaceutiques comprenant un dérivé de pyridine substitué
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
ATE432259T1 (de) 2005-07-20 2009-06-15 Lilly Co Eli Pyridinderivate als dipeptedyl-peptidase-hemmer
CN101277939A (zh) 2005-09-09 2008-10-01 布里斯托尔-迈尔斯斯奎布公司 无环ikur抑制剂
JP2009515934A (ja) 2005-11-18 2009-04-16 ノイロサーチ アクティーゼルスカブ 新規なキナゾリン誘導体及びこれらの医学的使用
DE602007004638D1 (de) 2006-07-20 2010-03-18 Amgen Inc Benzoädüisoxazol-derivate als c-kit-tyrosinkinase-hemmer zur behandlung von erkrankungen im zusammenhang mit der überproduktion von histamin
WO2008011110A2 (fr) 2006-07-20 2008-01-24 Amgen Inc. Composés hétérocycliques à bi-substitution amino et procédés d'utilisation
WO2008012532A2 (fr) 2006-07-27 2008-01-31 Astrazeneca Ab Composés chimiques 428
DE102006049452A1 (de) 2006-10-17 2008-05-08 Grünenthal GmbH Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln
WO2008066900A1 (fr) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International Analogues de 1,4-diamino rétigabine bicycliques en tant que modulateurs de canaux potassiques
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
WO2009019149A1 (fr) 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Dérivés de pyridinecarboxamide et de benzamide servant de ligands de taar1
CA2702469A1 (fr) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Antagonistes de ccr10
TWI504395B (zh) * 2009-03-10 2015-10-21 Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
WO2010102778A2 (fr) * 2009-03-10 2010-09-16 Grünenthal GmbH 3-aminoisoxazolopyridines substituées en tant que modulateurs de kcnq 2/3
TWI475020B (zh) * 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
TW201038565A (en) * 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2010102811A1 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9827248B2 (en) 2013-02-15 2017-11-28 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9877970B2 (en) 2013-02-15 2018-01-30 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US10398703B2 (en) 2013-02-15 2019-09-03 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US10966987B2 (en) 2013-02-15 2021-04-06 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof

Also Published As

Publication number Publication date
CN102348692A (zh) 2012-02-08
US20120252841A1 (en) 2012-10-04
CO6410292A2 (es) 2012-03-30
CA2755004A1 (fr) 2010-09-16
AU2010223513A1 (en) 2011-11-03
WO2010102811A1 (fr) 2010-09-16
IL214945A0 (en) 2011-11-30
TWI461197B (zh) 2014-11-21
PE20120790A1 (es) 2012-07-08
KR20110132590A (ko) 2011-12-08
ECSP11011348A (es) 2011-10-31
MX2011009369A (es) 2011-09-27
RU2011141188A (ru) 2013-04-20
JP5727946B2 (ja) 2015-06-03
US20100234372A1 (en) 2010-09-16
TW201034670A (en) 2010-10-01
BRPI1008939A2 (pt) 2016-03-15
AU2010223513B2 (en) 2014-12-04
CL2011002209A1 (es) 2012-02-10
AR075824A1 (es) 2011-04-27
JP2012520249A (ja) 2012-09-06
ZA201107444B (en) 2012-06-27
US8399673B2 (en) 2013-03-19
NZ595625A (en) 2012-10-26

Similar Documents

Publication Publication Date Title
EP2406229A1 (fr) 2-mercaptoquinoléine-3-carboxamides substitués utilisés comme modulateurs des canaux kcnq2/3
EP2406226B1 (fr) Nicotinamides substitués utilisés comme modulateurs des canaux kcnq2/3
EP2406224B1 (fr) 2-mercapto-3-aminopyridines substitués en tant que modulateurs de kcnq2/3
EP2406228B1 (fr) 3-amino-2-mercaptochinolines substituées en tant que modulateurs de KCNQ2/3
DE69722613T2 (de) 2,3,6-trisubstituierte 4(3h)-chinazolinone
DE69634416T2 (de) Chinolin-derivate
EP2350093B1 (fr) 4,5,6,7-tétrahydrothiénopyridines substituées, comme modulateurs des kcnq2/3 pour le traitement de la douleur, de l'épilepsie et de l'incontinence urinaire
EP2630123B1 (fr) 6-aminonicotinamides substitués utilisés comme modulateurs des canaux kcnq2/3
EP2406265A2 (fr) 3-aminoisoxazolopyridines substituées en tant que modulateurs de kcnq 2/3
EP2358681A1 (fr) Amides de l'acide 4-(1,2,3,4-tétrahydroisoquinoléin-2-yl)-4-oxo-butyrique substitués en tant que modulateurs de kcnq2/3
EP2609086B1 (fr) 2-oxo- et 2-thioxo-dihydroquinoléine-3-carboxamides substitués comme modulateurs de kcnq2/3
DE102005030524A1 (de) Substituierte Chinolone II
EP3150594A1 (fr) Dérivés d'n-sulfonyl homosérine lactone, procédé de préparation associé et utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110902

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1166060

Country of ref document: HK

17Q First examination report despatched

Effective date: 20150203

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170531

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1166060

Country of ref document: HK